...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical Cancer Investigation Journal >Metaplastic carcinoma of the breast: A report of two cases along with review of literature
【24h】

Metaplastic carcinoma of the breast: A report of two cases along with review of literature

机译：乳腺上皮化生癌2例并文献复习

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metaplastic carcinomas of breast are uncommon, representing 0.3% of invasive carcinomas of breast. We are reporting two cases of metaplastic carcinoma breast, one revealing rhabdomyoblastic and spindle cell differentiation and other revealing osteoclast like giant cells. Both were estrogen receptor, progesterone receptor and Her2u negative on immunohistochemistry. Early diagnosis of metaplastic carcinomas is essential as these tumors are usually triple negative and hence, do not respond to transtuzumab. Metaplastic carcinomas typically express HER1/epidermal growth factor receptor (EGFR), thus majority of metaplastic carcinomas are treated with EGFR inhibitors such as geftinib and cetuximab. Also, metaplastic carcinomas are associated with a worse prognosis with a disease free survival rate being 78.1% in metaplastic breast carcinomas compared with 91% in infiltrating duct carcinomas.
机译：乳腺增生性癌很少见，占乳腺浸润性癌的0.3％。我们报道了两例乳腺上皮化生癌，一例显示横纹母细胞和梭形细胞分化，另一例显示破骨细胞样巨细胞。两者均为免疫组织化学阴性的雌激素受体，孕激素受体和Her2u。化生癌的早期诊断至关重要，因为这些肿瘤通常是三阴性的，因此对转妥珠单抗无反应。化生癌通常表达HER1 /表皮生长因子受体（EGFR），因此大多数化生癌都用EGFR抑制剂（如吉非替尼和西妥昔单抗）治疗。而且，化生癌的预后更差，化生性乳腺癌的无病生存率为78.1％，而浸润性导管癌为91％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号